Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) represented a move of 0.97 percent or $-0.06 per share and closed its previous day trading session at $5.19. 2.72 Million Shares were traded in the last trading session with an Average Volume of 1.44 Million Shares. The stock currently has a Market Capitalization of 434.51 Million.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
The stock traded between $4.68 and $9.42 over 1-Year time period showing its price to sales ratio of 26.66. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-6.47 and 200-Day Simple Moving Average of $-27.12. Its Price to Free Cash Flow is 0 and Price to Book of 3.63.
Analyst’s recommended the stock as 1.5 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) reported its Actual EPS of $-0.3/share. The analysts offering Earnings Estimates for the company were believing that Progenics Pharmaceuticals Inc. could bring EPS of $-0.18/share. The difference between Actual EPS and Estimated EPS was -0.12 Percent. Thus showing an Earnings Surprise of -66.7 Percent.
Advance Auto Parts Inc (NYSE:AAP)
In the last trading session, Advance Auto Parts Inc (NYSE:AAP) added its value by 0.02% closing at the price of $177.71. The stock currently has market capitalization of 12.95 Billion, with average volume of 1.1 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Advance Auto Parts Inc (NYSE:AAP) is showing beta of 1.05. This particular value of beta suggests that Advance Auto Parts Inc (NYSE:AAP) has historically moved 105% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Advance Auto Parts Inc (NYSE:AAP) is at $6.46.
The stock currently has RSI of 56.24. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Advance Auto Parts, Inc., a leading automotive aftermarket parts provider in North America, serves both the professional installer and do-it-yourself customers. Advance Auto Parts stores and branches offer a broad selection of brand name, original equipment manufacturer (OEM) and private label automotive replacement parts, accessories, batteries and maintenance items for domestic and imported cars, vans, sport utility vehicles and light and heavy duty trucks. Advance Auto Parts have grown significantly as a result of comparable store sales growth, new store openings and strategic acquisitions. The acquisition allowed us to expand our geographic presence, Professional capabilities and overall scale to better serve customers.
Advance Auto Parts Inc (NYSE:AAP) topped its 52-week high price of $186.15 on 11/14/18 and 52-Week Low Price of $ 93.40 on 12/07/17. The Stock currently has P/E (price to earnings ttm) of 27.53 and Weekly volatility of 1.95% and monthly volatility of 2.64% respectively.